Bladder Cancer Immunotherapy: BCG and Beyond
Mycobacterium bovis bacillus Calmette-Guérin (BCG) has become the predominant conservative treatment for nonmuscle invasive bladder cancer. Its mechanism of action continues to be defined but has been shown to involve a T helper type 1 (Th1) immunomodulatory response. While BCG treatment is the curr...
Saved in:
| Main Authors: | Eric J. Askeland, Mark R. Newton, Michael A. O’Donnell, Yi Luo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/181987 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quality analysis of BCG vaccine for bladder cancer immunotherapy using Shewhart control charts
by: A. A. Savina, et al.
Published: (2024-03-01) -
Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy
by: Wojciech Krajewski, et al.
Published: (2020-04-01) -
Psoriasis exacerbation following intravesical BCG immunotherapy for bladder carcinoma: A case report
by: Yusuf Can Edek, et al.
Published: (2025-07-01) -
Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
by: Uyen To, et al.
Published: (2014-01-01) -
Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
by: S. Lukacs, et al.
Published: (2013-01-01)